Multianalyte LC–MS-Based Methods in Doping Control: What are The Implications for Doping Athletes?

Botrè, Francesco; Torre, Xavier de la; Mazzarino, Monica

doi:10.4155/bio-2016-0083

Cited by 10 publications

(8 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Regulatory agencies are increasingly tasked with detecting and identifying these designer steroids in products. Methods are being developed and new steroids are continuously being discovered in dietary supplements …”

Section: Introductionmentioning

confidence: 99%

Identification of the designer steroid Androsta‐3,5‐diene‐7,17‐dione in a dietary supplement

Lorenz

Toomey

Lanzarotta

et al. 2019

Drug Testing and Analysis

View full text Add to dashboard Cite

A liquid chromatography‐mass spectrometry (LC–MS) screen for known anabolic‐androgenic steroids in a dietary supplement product marketed for “performance enhancement” detected an unknown compound having steroid‐like spectral characteristics. The compound was isolated using high performance liquid chromatography with ultraviolet detection (HPLC–UV) coupled with an analytical scale fraction collector. After the compound was isolated, it was then characterized using gas chromatography with simultaneous Fourier Transform infrared detection and mass spectrometry (GC–FT–IR–MS), liquid chromatography–high resolution accurate mass–mass spectrometry (LC–HRAM–MS) and nuclear magnetic resonance (NMR). The steroid had an accurate mass of m/z 285.1847 (error−0.57 ppm) for the protonated species [M + H]+, corresponding to a molecular formula of C19H24O2. Based on the GC–FT–IR–MS data, NMR data, and accurate mass, the compound was identified as androsta‐3,5‐diene‐7,17‐dione. Although this is not the first reported identification of this designer steroid in a dietary supplement, the data provided adds information for identification of this compound not previously reported. This compound was subsequently detected in another dietary supplement product, which contained three additional active ingredients.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of the designer steroid Androsta‐3,5‐diene‐7,17‐dione in a dietary supplement

Lorenz

Toomey

Lanzarotta

et al. 2019

Drug Testing and Analysis

View full text Add to dashboard Cite

show abstract

“…Todas las muestras se recibieron y registraron para su distribución y análisis inicial de tamizaje empleando los métodos analíticos internos de operación, los cuales están validados de acuerdo a las normas internacionales aplicables, así como a la información científica disponible en su momento (Arnedo, Ricarte, Martínez y Salvador, 1998;Mareck, Geyer, Opfermann, Thevis y Schänzer, 2008;Kickman y Cowan, 2009;Sottas, Robinson, Rabin y Saugy, 2011;Botrè, De la Torre y Mazzarino, 2016). Además se siguieron las indicaciones que se mencionan en los diferentes documentos técnicos y guías emitidas por la WADA-AMA, (WADA-AMA, TD-DL, 2010WADA-AMA, EAAS, 2004WADA-AMA, IRMS, 2014;WADA-AMA, IDCR, 2010WADA-AMA, TD-MRPL, 2009WADA-AMA, NAND, 2004;WADA-AMA, TD-EPO, 2009WADA-AMA, LDOC, 2009; WADA-AMA, ICOC, 2009) con la finalidad de detectar las sustancias dopantes o sus metabolitos o sus marcadores descritos en la lista de sustancias y métodos prohibidos que para tal caso la WADA-AMA publica al inicio de cada año.…”

Section: Métodosunclassified

Sustancias dopantes y su incidencia: una visión retrospectiva del laboratorio nacional de prevención y control del dopaje de México

et al. 2018

View full text Add to dashboard Cite

The use of banned substances to increase athletes' performance has been a scourge in international sport. In this sense, the World Anti-Doping Agency (WADA-AMA) has implemented a series of standards that harmonize the fight against doping. In particular, accredited WADA-AMA laboratories play an important role in the eradication of sports doping. This report shows the data obtained in the National Laboratory of Prevention and Control of Doping (LNPCD-CONADE) according to the incidence of Adverse Analytical Findings (AAF) in the 2009-2015 interval, which were obtained from the analysis of a total of 18,085 biological doping-control samples. The distribution of samples was analyzed as a function of gender, type of sport either in competition or out of competition, as well as the prevalence of AAF during the period of time analyzed and the relation regarding group of doping substance and type of sport. The data presented here were compared with those reported worldwide by the WADA-AMA and it was observed that in the cases of substances of the S1 group, the percentage reported by the LNPCD-CONADE is higher than the one reported worldwide. The opposite was observed for AAF presented by some substance from Groups S6 and S8. Likewise, a higher prevalence in the use of doping substances by male athletes (75%) is observed compared to that observed in female athletes (25%). The sports with the highest number of AAF detected in the laboratory were baseball, cycling, and athletics.

show abstract

“…For reprint orders, please contact: reprints@futuremedicine.com tions for doping athletes? [13] and 'Running ahead of doping: analytical advances and challenges faced by modern laboratories ahead of Rio 2016' [14], both f eaturing in our most-read list of 2016.…”

Section: Sankeetha Nadarajahmentioning

confidence: 99%

Welcome to Volume 9 of Bioanalysis

Nadarajah

2016

Bioanalysis

View full text Add to dashboard Cite

show abstract

Multianalyte LC–MS-Based Methods in Doping Control: What are The Implications for Doping Athletes?

Cited by 10 publications

References 17 publications

Identification of the designer steroid Androsta‐3,5‐diene‐7,17‐dione in a dietary supplement

Identification of the designer steroid Androsta‐3,5‐diene‐7,17‐dione in a dietary supplement

Sustancias dopantes y su incidencia: una visión retrospectiva del laboratorio nacional de prevención y control del dopaje de México

Welcome to Volume 9 of Bioanalysis

Contact Info

Product

Resources

About